HUMA Rule 144 Notice: 1,100,000 Shares via UBS Listed for Sale

Rhea-AI Filing Summary

Humacyte, Inc. notice of proposed sale reports an intended sale of 1,100,000 common shares through UBS Financial Services on or about 08/19/2025 on NASDAQ, with an aggregate market value of $1,790,244.50. The filing shows the shares were originally acquired on 08/26/2021 as early-stage investor holdings converted to Humacyte shares when the company went public via a SPAC, and payment for the original acquisition was in cash. The filer also reported sales during the prior three months: 549,360 shares sold on 08/18/2025 for gross proceeds of $997,429. The filing includes the filers representation that no undisclosed material adverse information is known.

Positive

• Planned sale disclosed with broker and market details (UBS, NASDAQ, approximate date 08/19/2025), supporting market transparency
• Acquisition origin disclosed (conversion from early-stage investor in AHAC on 08/26/2021), which clarifies holding history
• Recent sales reported (549,360 shares on 08/18/2025 for $997,429), providing concrete liquidity activity

Negative

• Planned sale size is meaningful in absolute terms (1,100,000 shares; aggregate market value $1,790,244.50) and could add supply to the market
• Seller is monetizing a legacy position (converted SPAC shares), which may indicate continued selling by pre-public investors

Insights

Securities Analyst

TL;DR: Holder plans to sell 1.1M HUMA shares (~0.70% of outstanding) via UBS, after selling ~549K shares one day earlier.

The filing documents a routine Rule 144 notice: a block of 1,100,000 common shares is scheduled for sale through a broker on 08/19/2025. The filer discloses acquisition origin (converted early-stage investor shares from the SPAC transaction, acquired 08/26/2021) and prior recent sales of 549,360 shares on 08/18/2025 for $997,429. The position size relative to reported outstanding shares (158,372,173) is approximately 0.70%, indicating modest potential issuance to the market. This is a disclosure of intent under Rule 144 rather than a corporate operational indicator.

Corporate Governance Specialist

TL;DR: The filing is a compliance disclosure showing a historical investor liquidating converted SPAC-era holdings.

The notice provides required seller information and acquisition provenance: shares trace to an early-stage investor position in AHAC converted at the companys public listing. The signature representation affirms no undisclosed material adverse information is known to the seller. From a governance standpoint, the filing is a standard transparency step supporting orderly secondary market sales; it does not by itself signal corporate governance actions or changes.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	1100000	1790244.5	158372173	08/19/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	08/26/2021	EARLY STAGE INVESTOR IN AHAC. SHARES WERE CONVERTED TO HUMA SHARES WHEN THE COMPANY WENT PUBLIC VIA SPAC.	HUMACYTE INC			18930004	08/26/2021	CASH

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
AYABUDGE LLC 95 ROSEMONT DRIVE DURHAM NC 27713	COMMON	08/18/2025	549360	997429

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Humacyte (HUMA) Form 144 filed here disclose?

The notice reports an intended sale of 1,100,000 common shares through UBS on or about 08/19/2025 on NASDAQ, with an aggregate market value of $1,790,244.50.

When and how were the shares being sold originally acquired?

The shares were acquired on 08/26/2021 as an early-stage investor position in AHAC that converted to Humacyte shares when the company went public via a SPAC; payment at acquisition was cash.

Has the filer sold any Humacyte shares recently?

Yes. The filer sold 549,360 common shares on 08/18/2025 for gross proceeds of $997,429.

How large is the proposed sale relative to Humacyte's outstanding shares?

The filing lists 158,372,173 shares outstanding; the proposed 1,100,000 share sale represents about 0.70% of that total.

Does the filing state any undisclosed material information about Humacyte?

By signing the notice the seller represents they do not know any material adverse information about the issuer that has not been publicly disclosed.